Imatinib treatment: Specific issues related to safety, fertility, and pregnancy

被引：133

作者：

Hensley, ML ^{[1
]}

Ford, JM ^{[1
]}

机构：

[1] Novartis Pharmaceut, Dept Oncol Clin Res, Basel, Switzerland

来源：

SEMINARS IN HEMATOLOGY | 2003年 / 40卷 / 02期

关键词：

D O I：

10.1053/shem.2003.50038

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：21 / 25

页数：5

共 11 条

[1]

[Anonymous], 1998, REVISED COMMON TOXIC

[2]

Buchdunger E, 1996, CANCER RES, V56, P100

[3]

Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139

[4] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].

Druker, BJ ;

Sawyers, CL ;

Kantarjian, H ;

Resta, DJ ;

Reese, SF ;

Ford, JM ;

Capdeville, R ;

Talpaz, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042

[5] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].

Druker, BJ ;

Talpaz, M ;

Resta, DJ ;

Peng, B ;

Buchdunger, E ;

Ford, JM ;

Lydon, NB ;

Kantarjian, H ;

Capdeville, R ;

Ohno-Jones, S ;

Sawyers, CL .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037

[6] Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor [J].

Heinrich, MC ;

Griffith, DJ ;

Druker, BJ ;

Wait, CL ;

Ott, KA ;

Zigler, AJ .

BLOOD, 2000, 96 (03) :925-932

[7] Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. [J].

Kantarjian, H ;

Sawyers, C ;

Hochhaus, A ;

Guilhot, F ;

Schiffer, C ;

Gambacorti-Passerini, C ;

Niederwieser, D ;

Resta, D ;

Capdeville, R ;

Zoellner, U ;

Talpaz, M ;

Druker, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) :645-652

[8] Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia [J].

O'Brien, SG ;

Guilhot, F ;

Larson, RA ;

Gathmann, I ;

Baccarani, M ;

Cervantes, F ;

Cornelissen, JJ ;

Fischer, T ;

Hochhaus, A ;

Hughes, T ;

Lechner, K ;

Nielsen, JL ;

Rousselot, P ;

Reiffers, J ;

Saglio, G ;

Shepherd, J ;

Simonsson, B ;

Gratwohl, A ;

Goldman, JM ;

Kantarjian, H ;

Taylor, K ;

Verhoef, G ;

Bolton, AE ;

Capdeville, R ;

Druker, BJ ;

Durrant, S ;

Schwarer, A ;

Joske, D ;

Seymour, J ;

Grigg, A ;

Ma, D ;

Arthur, C ;

Bradstock, K ;

Joshua, D ;

Louwagie, A ;

Martiat, P ;

Straetmans, N ;

Bosly, A ;

Shustik, C ;

Lipton, J ;

Forrest, D ;

Walker, I ;

Roy, DC ;

Rubinger, M ;

Bence-Bruckler, I ;

Kovacs, M ;

Turner, AR ;

Birgens, H ;

Bjerrum, O ;

Facon, T .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (11) :994-1004

[9] ARG tyrosine kinase activity is inhibited by ST1571 [J].

Okuda, K ;

Weisberg, E ;

Gilliland, DG ;

Griffin, JD .

BLOOD, 2001, 97 (08) :2440-2448

[10] Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study [J].

Sawyers, CL ;

Hochhaus, A ;

Feldman, E ;

Goldman, JM ;

Miller, CB ;

Ottmann, OG ;

Schiffer, CA ;

Talpaz, M ;

Guilhot, F ;

Deininger, MWN ;

Fischer, T ;

O'Brien, SG ;

Stone, RM ;

Gambacorti-Passerini, CB ;

Russell, NH ;

Reiffers, JJ ;

Shea, TC ;

Chapuis, B ;

Coutre, S ;

Tura, S ;

Morra, E ;

Larson, RA ;

Saven, A ;

Peschel, C ;

Gratwohl, A ;

Mandelli, F ;

Ben-Am, M ;

Gathmann, I ;

Capdeville, R ;

Paquette, RL ;

Druker, BJ .

BLOOD, 2002, 99 (10) :3530-3539

← 1 2 →